Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Endogenous exosomes act as decoys for SARS-CoV-2

A recent study published in the journal PLoS Biology discussed exosomes as potential decoys for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

20 Sep 2022

Molecular engineered low-cost highly effective RBD-based COVID vaccine

In a recent study posted to the bioRxiv* preprint server, an international team of researchers developed a second-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen (RBD-J6) by molecular engineering with two additional amino acid (aa) substitutions (S383D and L518D mutations) in a hydrophobic cryptic RBD core epitope to enhance stability and expression against SARS-CoV-2 variants of concern (VOCs).

19 Sep 2022

U of A research findings could give scientists the upper hand in tackling SARS-CoV-2

University of Alberta research shows how cell membranes play a much larger role than previously understood in allowing spike proteins on viruses to infect cells.

16 Sep 2022

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

A new study maps the escape mutations found in various strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could cause them to escape neutralization by antibodies or detection by rapid antigen tests that rely on antibody binding for a positive result.

16 Sep 2022

Development of improved monoclonal antibodies against SARS-CoV-2

In a new study, researchers explored strategies for the development of effective monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2022

Research shows a complex relationship between vaping and SARS-CoV-2 infection

In a recent study posted to the bioRxiv* pre-print server, researchers at the University of California, Riverside investigated the effects of electronic cigarette (EC) use as a risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

Defensosomes versus COVID-19

In a recent study published in the journal PLoS Biology, researchers investigated the role of angiotensin-converting enzyme 2 (ACE2)-containing defensive exosomes, or 'defensosomes' against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

14 Sep 2022

Customized bivalent mRNA COVID boosters protect against BA.5 Omicron variant

In a recent study posted to the bioRxiv* pre-print server, researchers from Washington University School of Medicine, Moderna, Inc, and the U.S. National Institutes of Health tested two bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines based on the messenger ribonucleic acid (mRNA) platform.

14 Sep 2022

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

A new study suggested that an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine induced mucosal immune responses in mice.

14 Sep 2022

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.

14 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

How effective is vitamin D supplementation in COVID-19?

The current paper addresses the considerable evidence now supporting the efficacy of vitamin D in COVID-19, as well as its safety.

13 Sep 2022

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers in the United States demonstrated the efficacy of a novel biopolymer, N-dihydrogalactochitosan (GC), as an adjuvant for next-generation mucosal coronavirus disease 2019 (COVID-19) vaccine.

12 Sep 2022

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

Researchers provided a summary of SARS-CoV-2 infections among children pre- and post-SARS-CoV-2 Delta and Omicron variants of concern (VOCs) emergence.

12 Sep 2022

What is the impact of COVID-19 vaccination on erectile function?

A recent study reported that COVID-19 vaccination does not elevate the risk of erectile dysfunction.

12 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

In a recent study posted to the bioRxiv* preprint server, researchers in Germany and the United Kingdom investigated the interferon responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant and SARS-CoV-2 Omicron sub-variants BA.1 and BA.5, and their efficacy in protecting cells from influenza A virus super-infection.

12 Sep 2022

Discovery of antibodies that may eliminate the need for COVID vaccines

...

11 Sep 2022

All SARS-CoV-2 variants neutralized by a potent new antibody

Researchers describe a mouse model used to generate a VH1-2 heavy chain (HC)- and Vκ1-33 light chain (LC)-based recombinant antibody that broadly neutralized all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the newly emergent Omicron sub-variant BA.5.

9 Sep 2022

Can preclinical COVID-19 models help unlock mystery of long-COVID?

In a recently published article in the journal PLOS PATHOGENS, scientists have summarized acute and prolonged clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The review also provides an overview of the potency and utility of preclinical animal models to understand the mechanistic details of acute and long coronavirus disease 2019 (COVID-19).

8 Sep 2022

Angiotensin News and Research

Further Reading

Endogenous exosomes act as decoys for SARS-CoV-2

Molecular engineered low-cost highly effective RBD-based COVID vaccine

U of A research findings could give scientists the upper hand in tackling SARS-CoV-2

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

Development of improved monoclonal antibodies against SARS-CoV-2

Research shows a complex relationship between vaping and SARS-CoV-2 infection

Defensosomes versus COVID-19

Customized bivalent mRNA COVID boosters protect against BA.5 Omicron variant

Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity

Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

How effective is vitamin D supplementation in COVID-19?

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

Review of COVID-19 in children before and after SARS-CoV-2 Delta and Omicron variant emergence

What is the impact of COVID-19 vaccination on erectile function?

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

Discovery of antibodies that may eliminate the need for COVID vaccines

All SARS-CoV-2 variants neutralized by a potent new antibody

Can preclinical COVID-19 models help unlock mystery of long-COVID?

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News